Application of proteomic technologies for prostate cancer detection, prognosis, and tailored therapy

Prostate cancer affects 3 in 10 men over the age of 50 years, and, unfortunately, the clinical course of the disease is poorly predicted. At present, there is no means that can distinguish indolent from aggressive/metastatic tumors. Thus, a personalized clinical approach could be helpful in diagnosing clinically relevant disease and guiding appropriate patient therapy. Individualized medicine requires a deep knowledge of the molecular mechanisms underpinning prostate cancer carcinogenesis. Proteomics may be the most powerful way to uncover biomarkers of detection, prognosis, and prediction, as proteins do the work of the cell and represent the majority of the diagnostic markers and drug targets today. Proteomic technologies are rapidly advancing beyond the two-dimensional gel separation techniques of the past to new types of mass spectrometry and protein microarray analyses. Biological fluids and tissue-cell proteomes from men with prostate cancer are being explored to identify diagnostic and prognostic biomarkers and therapeutic targets using these new proteomic approaches. Traditional and novel proteomic technology and their application to prostate cancer studies in translational research will be presented and discussed in this review. Proteomics coupled with powerful nanotechnology-based biomarker discovery approaches may provide a new and exciting opportunity for body fluid-borne biomarker discovery and characterization. While innovative mass spectrometry technology and nanotrap could be applied to improve the discovery and measurement of biomarkers for the early detection of prostate cancer, the use of tissue proteomic tools such as the reverse-phase protein microarray may provide new approaches for personalization of therapies tailored to each tumor’s unique pathway activation network.

[1]  E. Petricoin,et al.  Signal pathway profiling of prostate cancer using reverse phase protein arrays , 2003, Proteomics.

[2]  C. Tso,et al.  Androgen deprivation induces selective outgrowth of aggressive hormone-refractory prostate cancer clones expressing distinct cellular and molecular properties not present in parental androgen-dependent cancer cells. , 2000, Cancer journal.

[3]  G. Schrauzer,et al.  Selenium/cadmium ratios in human prostates , 2005, Biological Trace Element Research.

[4]  Depletion of high-abundance proteins from serum by immunoaffinity chromatography: a MALDI-FT-MS study. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[5]  M. Rubin,et al.  Integrative biology of prostate cancer progression. , 2006, Annual review of pathology.

[6]  E. Petricoin,et al.  Nanotechnology in clinical proteomics. , 2007, Nanomedicine.

[7]  J. Richie,et al.  Chromatofocusing fractionation and two‐dimensional difference gel electrophoresis for low abundance serum proteins , 2005, Proteomics.

[8]  P. Carroll,et al.  Androgen deprivation therapy for the treatment of prostate cancer: consider both benefits and risks. , 2009, European urology.

[9]  J. Bouchal,et al.  Urine markers in monitoring for prostate cancer , 2010, Prostate Cancer and Prostatic Diseases.

[10]  E. Petricoin,et al.  Putting the "bio" back into biomarkers: orienting proteomic discovery toward biology and away from the measurement platform. , 2008, Clinical chemistry.

[11]  S. Pang,et al.  Proteomic comparison of prostate cancer cell lines LNCaP‐FGC and LNCaP‐r reveals heatshock protein 60 as a marker for prostate malignancy , 2006, The Prostate.

[12]  J. Krijgsveld,et al.  Mass Spectrometric Identification of Human Prostate Cancer-derived Proteins in Serum of Xenograft-bearing Mice* , 2006, Molecular & Cellular Proteomics.

[13]  R. Caprioli,et al.  Molecular imaging of biological samples: localization of peptides and proteins using MALDI-TOF MS. , 1997, Analytical chemistry.

[14]  P. Loehrer.  Assessing Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial , 2007 .

[15]  A. Butte,et al.  AILUN: reannotating gene expression data automatically , 2007, Nature Methods.

[16]  L. Hood,et al.  Deep depletion of abundant serum proteins reveals low‐abundant proteins as potential biomarkers for human ovarian cancer , 2009, Proteomics. Clinical applications.

[17]  P. Clark,et al.  Chemokine Markers Predict Biochemical Recurrence of Prostate Cancer following Prostatectomy , 2008, Clinical Cancer Research.

[18]  E. Petricoin,et al.  New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. , 2001, Urology.

[19]  A. Coolen,et al.  The potential of optical proteomic technologies to individualize prognosis and guide rational treatment for cancer patients , 2009, Targeted Oncology.

[20]  K. Chapman,et al.  A systematic review of the effect of diet in prostate cancer prevention and treatment. , 2009, Journal of human nutrition and dietetics : the official journal of the British Dietetic Association.

[21]  S. Pennington,et al.  Protein and peptides in pictures: Imaging with MALDI mass spectrometry , 2008, Proteomics.

[22]  S. Nishizuka,et al.  Reverse-phase protein lysate microarrays for cell signaling analysis , 2008, Nature Protocols.

[23]  Patrick Ducoroy,et al.  Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. , 2007, Journal of proteome research.

[24]  Gerhard Jakse,et al.  Identifying prostate carcinoma by MALDI-Imaging. , 2007, International journal of molecular medicine.

[25]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. , 2002, The Journal of urology.

[26]  Weidong Zhou,et al.  Core-Shell Hydrogel Particles Harvest, Concentrate and Preserve Labile Low Abundance Biomarkers , 2009, PloS one.

[27]  J. Heil,et al.  Reference map for liquid chromatography-mass spectrometry-based quantitative proteomics. , 2009, Analytical biochemistry.

[28]  D. Chan,et al.  Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias. , 2008, Clinical chemistry.

[29]  E. Crawford,et al.  Screening for prostate cancer: current recommendations. , 2004, The Urologic clinics of North America.

[30]  D. Chan,et al.  Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. , 2005, Clinical chemistry.

[31]  J. Dekernion,et al.  Diagnosis and treatment of prostate cancer. , 1998, American family physician.

[32]  C. Huggins,et al.  STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[33]  P. Walsh,et al.  Chemoprevention of prostate cancer. , 2010, The New England journal of medicine.

[34]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[35]  H. Leung,et al.  Evaluation of an in vitro model of androgen ablation and identification of the androgen responsive proteome in LNCaP cells , 2007, Proteomics.

[36]  T. Noda,et al.  MALDI-based imaging mass spectrometry revealed abnormal distribution of phospholipids in colon cancer liver metastasis. , 2007, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[37]  Virginia Espina,et al.  Concentration and preservation of very low abundance biomarkers in urine, such as human growth hormone (hGH), by Cibacron Blue F3G-A loaded hydrogel particles , 2008, Nano research.

[38]  M. Barry.  Screening for prostate cancer among men 75 years of age or older. , 2008, The New England journal of medicine.

[39]  V. Bumelis,et al.  Analysis of Cibacron blue F3G-A interaction with therapeutic proteins by MALDI-TOF mass spectrometry. , 2008, Biomedical chromotography.

[40]  E. Petricoin,et al.  The blood peptidome: a higher dimension of information content for cancer biomarker discovery , 2006, Nature Reviews Cancer.

[41]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[42]  E. Sacco,et al.  Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia. , 2009, Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica.

[43]  P. Chaurand,et al.  Monitoring Mouse Prostate Development by Profiling and Imaging Mass Spectrometry*S , 2008, Molecular & Cellular Proteomics.

[44]  D. Landsittel,et al.  Early identification of individuals with prostate cancer in negative biopsies. , 2004, The Journal of urology.

[45]  Emanuel F Petricoin,et al.  Nanoparticles: potential biomarker harvesters. , 2006, Current opinion in chemical biology.

[46]  M. Gross,et al.  Beta-2-microglobulin is an androgen-regulated secreted protein elevated in serum of patients with advanced prostate cancer. , 2007, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  Jianjun Yu,et al.  Humoral Response Profiling Reveals Pathways to Prostate Cancer Progression*S , 2008, Molecular & Cellular Proteomics.

[48]  M. D. Lloyd,et al.  α‐Methylacyl‐CoA racemase – an ‘obscure’ metabolic enzyme takes centre stage , 2008, The FEBS journal.

[49]  Sze Chuen Cesar Wong,et al.  Advanced proteomic technologies for cancer biomarker discovery , 2009, Expert review of proteomics.

[50]  Ziding Feng,et al.  Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. , 2006, Journal of the National Cancer Institute.

[51]  Dean Brenner,et al.  Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays , 2007, Nature Methods.

[52]  D. Chan,et al.  SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. , 2008, Clinical chemistry.

[53]  Shandra S. Wilson.  Prostate cancer screening , 2005, Comprehensive therapy.

[54]  N. Zaffaroni,et al.  Novel PVA-based hydrogel microparticles for doxorubicin delivery. , 2008, Biomacromolecules.

[55]  C. Roehrborn,et al.  The utility of serum prostatic-specific antigen in the management of men with benign prostatic hyperplasia , 2008, International Journal of Impotence Research.

[56]  K. Camphausen,et al.  Urine Analysis and Protein Networking Identify Met as a Marker of Metastatic Prostate Cancer , 2009, Clinical Cancer Research.

[57]  E. Petricoin,et al.  Laser Capture Microdissection , 1996, Science.

[58]  Juni Palmgren,et al.  A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. , 2002, The New England journal of medicine.

[59]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[60]  S. Egawa,et al.  Proteome analysis of prostate cancer , 2005, Prostate Cancer and Prostatic Diseases.

[61]  L. M. Glodé,et al.  A comprehensive characterization of the peptide and protein constituents of human seminal fluid , 2004, The Prostate.

[62]  G. Auer,et al.  Polypeptide Expression in Prostate Hyperplasia and Prostate Adenocarcinoma , 2000, Analytical cellular pathology : the journal of the European Society for Analytical Cellular Pathology.

[63]  M. Kostrzewa,et al.  Immuno‐MALDI‐TOF MS: New perspectives for clinical applications of mass spectrometry , 2009, Proteomics.

[64]  Kermit K. Murray,et al.  Microfluidic chips for mass spectrometry-based proteomics. , 2009, Journal of mass spectrometry : JMS.

[65]  Caroline Dive,et al.  Quantitative mass spectrometry-based techniques for clinical use: Biomarker identification and quantification , 2008, Journal of Chromatography B.

[66]  M. Barry.  Prostate-Specific–Antigen Testing for Early Diagnosis of Prostate Cancer , 2001 .

[67]  J. Neoptolemos,et al.  Heat shock protein expression independently predicts clinical outcome in prostate cancer. , 2000, Cancer research.

[68]  J. Crowley,et al.  Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. , 2004, The New England journal of medicine.

[69]  Yue Fan,et al.  2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. , 2009, Journal of proteome research.

[70]  Lisa H Cazares,et al.  Imaging Mass Spectrometry of a Specific Fragment of Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Kinase Kinase 2 Discriminates Cancer from Uninvolved Prostate Tissue , 2009, Clinical Cancer Research.

[71]  Emanuel F. Petricoin,et al.  Serum Proteomic Analysis Identifies a Highly Sensitive and Specific Discriminatory Pattern in Stage 1 Breast Cancer , 2007, Annals of Surgical Oncology.

[72]  Douglas Benson,et al.  High-resolution quantitative imaging of mammalian and bacterial cells using stable isotope mass spectrometry , 2006, Journal of biology.

[73]  Ruedi Aebersold,et al.  Mass Spectrometry-based Expression Profiling of Clinical Prostate Cancer , 2005, Molecular & Cellular Proteomics.

[74]  Detlev Suckau,et al.  Classification of HER2 receptor status in breast cancer tissues by MALDI imaging mass spectrometry. , 2010, Journal of proteome research.

[75]  M. Rubin,et al.  Pathway biomarker profiling of localized and metastatic human prostate cancer reveal metastatic and prognostic signatures. , 2009, Journal of proteome research.

[76]  Weidong Zhou,et al.  Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. , 2008, Nano letters.

[77]  N. Breslow,et al.  Latent carcinoma of prostate at autopsy in seven areas. Collaborative study organized by the International Agency for Research on Cancer, Lyons, France , 1977, International journal of cancer.

[78]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[79]  G. Untergasser,et al.  Aging of the prostate epithelial stem/progenitor cell , 2008, Experimental Gerontology.

[80]  C. Stephan,et al.  Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. , 2008, Journal of proteome research.

[81]  Kevin Camphausen,et al.  The needle in the haystack: Application of breast fine‐needle aspirate samples to quantitative protein microarray technology , 2007, Cancer.

[82]  O. Bratt.  Hereditary prostate cancer: clinical aspects. , 2002, The Journal of urology.

[83]  G. Wright,et al.  Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures , 1999, Prostate Cancer and Prostatic Diseases.

[84]  M. Resnick,et al.  The influence of chronic inflammation in prostatic carcinogenesis: a 5-year followup study. , 2006, The Journal of urology.

[85]  E. Petricoin,et al.  Reverse phase protein microarrays for monitoring biological responses. , 2007, Methods in molecular biology.

[86]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[87]  J. Garin,et al.  Isotope dilution strategies for absolute quantitative proteomics. , 2009, Journal of proteomics.

[88]  M. Clements,et al.  Clinical collection and protein properties of expressed prostatic secretions as a source for biomarkers of prostatic disease. , 2009, Journal of proteomics.

[89]  P. O’Farrell.  High resolution two-dimensional electrophoresis of proteins. , 1975, The Journal of biological chemistry.

[90]  A. Salvador,et al.  Clinical Quantitation of Prostate-specific Antigen Biomarker in the Low Nanogram/Milliliter Range by Conventional Bore Liquid Chromatography-Tandem Mass Spectrometry (Multiple Reaction Monitoring) Coupling and Correlation with ELISA Tests , 2009, Molecular & Cellular Proteomics.

[91]  Mun'delanji C. Vestergaard,et al.  A rapid sample pretreatment protocol: improved sensitivity in the detection of a low-abundant serum biomarker for prostate cancer. , 2007, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[92]  E. Southern,et al.  Multiplex target protein imaging in tissue sections by mass spectrometry--TAMSIM. , 2007, Rapid communications in mass spectrometry : RCM.

[93]  Javier Hernandez,et al.  Diagnosis and treatment of prostate cancer. , 2004, The Medical clinics of North America.

[94]  C. Huggins,et al.  Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate , 1941, CA: a cancer journal for clinicians.

[95]  Lawrence D True,et al.  Differential expression of CD10 in prostate cancer and its clinical implication , 2007, BMC urology.

[96]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[97]  Tony Pawson,et al.  High-throughput phosphotyrosine profiling using SH2 domains. , 2007, Molecules and Cells.

[98]  B. G. Blijenberg,et al.  Screening and prostate-cancer mortality in a randomized European study. , 2009, The New England journal of medicine.

[99]  H. Scher,et al.  Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. , 2009, The Lancet. Oncology.

[100]  Ehsan Gazi,et al.  Discrimination of prostate cancer cells and non-malignant cells using secondary ion mass spectrometry. , 2008, The Analyst.

[101]  Allan S Hoffman,et al.  Hydrogels for biomedical applications. , 2002, Advanced drug delivery reviews.

[102]  M. Gross,et al.  β-2-Microglobulin Is an Androgen-Regulated Secreted Protein Elevated in Serum of Patients with Advanced Prostate Cancer , 2007, Clinical Cancer Research.

[103]  B. Haab.  Antibody–lectin sandwich arrays for biomarker and glycobiology studies , 2010, Expert review of proteomics.

[104]  G. Zummo,et al.  Immunohistochemical evaluation of PCNA, p53, HSP60, HSP10 and MUC-2 presence and expression in prostate carcinogenesis. , 2003, Anticancer research.

[105]  Hailing Lu,et al.  Humoral immunity directed against tumor-associated antigens as potential biomarkers for the early diagnosis of cancer. , 2008, Journal of proteome research.